Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2010

View Archived Issues

Netupitant shows promise to treat overactive bladder in preclinical studies

Researchers describe new anti-inflammatory MAPK 14 inhibitors

NGP-328 is selected as clinical candidate for Alzheimer's disease

Stem cell research funding ban does not affect International Stem Cell

SuperGen discovers new inhibitors of tyrosine-protein kinase receptor UFO

Wyeth claims new cannabinoid CB2 receptor agonists

Recordati discloses new metabotropic glutamate mGlu5 receptor antagonists

FDA accepts Sanofi Pasteur's BLA to expand Menactra indication

Organon identifies new TRPV1 ligands

Taisho Pharma describes new histamine H3 receptor antagonists

NIH renews research funding for Homspera in radiation-induced lung injury

Pharming prepares to submit Rhucin BLA to FDA

FDA approves phase II trial protocol of CH-4051 in rheumatoid arthritis

Shire's VPRIV approved in Europe for type 1 Gaucher's disease

Vanda Pharma begins phase III tasimelteon trial in blind patients with N24HSWD

Lotus Pharma initiates phase I trial of (R)-bambuterol in China

FDA issues refuse to file letter for trastuzumab-DM1 BLA

Cardioxyl begins phase IIa trial of CXL-1020 for heart failure

DIDS improves yield and preserves integrity of isolated pancreatic islets

Karo Bio reviews phase III eprotirome program in hypercholesterolemia

Octapharma USA voluntarily withdraws lots of Octagam 5% from market

Actelion to exclusively distribute Basilea's Toctino in Canada

FDA grants orphan drug status to Kineret in CAPS

LIM-0705 reverses tacrolimus-induced metabolic defects in phase Ib trial

FDA approves Novartis' Tekamlo for hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...